Recombinant Anti-Sumo 3 antibody [1H9L17] (ab203570)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [1H9L17] to Sumo 3
- Suitable for: ICC/IF, Flow Cyt, IHC-P, WB
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-Sumo 3 antibody [1H9L17]
See all Sumo 3 primary antibodies -
Description
Rabbit monoclonal [1H9L17] to Sumo 3 -
Host species
Rabbit -
Tested applications
Suitable for: ICC/IF, Flow Cyt, IHC-P, WBmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide corresponding to Human Sumo 3 aa 50 to the C-terminus.
Database link: P55854 -
Positive control
- WB: Mouse oesophagus, skin, skeletal muscle lysates; Human cell line lysates Jurkat and U2OS cells; IHC: Human colon carcinoma tissue; ICC/IF: U2OS, MCF7 cell lines Flow Cyt: Jurkat cells
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.09% Sodium azide
Constituent: 99% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
1H9L17 -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab203570 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
Use a concentration of 4 - 6 µg/ml.
|
|
Flow Cyt |
Use at an assay dependent concentration.
Use at 0.5-1 µg/test |
|
IHC-P |
Use a concentration of 4 - 6 µg/ml. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
WB |
Use a concentration of 2 - 3 µg/ml. Predicted molecular weight: 11 kDa.
|
Notes |
---|
ICC/IF
Use a concentration of 4 - 6 µg/ml. |
Flow Cyt
Use at an assay dependent concentration. Use at 0.5-1 µg/test |
IHC-P
Use a concentration of 4 - 6 µg/ml. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
WB
Use a concentration of 2 - 3 µg/ml. Predicted molecular weight: 11 kDa. |
Target
-
Function
Ubiquitin-like protein which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Does not seem to be involved in protein degradation and may function as an antagonist of ubiquitin in the degradation process. Plays a role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4. -
Tissue specificity
Expressed predominantly in liver. -
Sequence similarities
Belongs to the ubiquitin family. SUMO subfamily.
Contains 1 ubiquitin-like domain. -
Post-translational
modificationsPolymeric chains can be formed through Lys-11 cross-linking.
Cleavage of precursor form by SENP1, SENP2 or SENP5 is necessary for function. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 6612 Human
- Entrez Gene: 20610 Mouse
- Omim: 602231 Human
- SwissProt: P55854 Human
- SwissProt: Q9Z172 Mouse
- Unigene: 474005 Human
- Unigene: 24433 Mouse
-
Alternative names
- Small ubiquitin like modifier 3 antibody
- Small ubiquitin related modifier 3 antibody
- Small ubiquitin-related modifier 3 antibody
see all
Images
-
All lanes : Anti-Sumo 3 antibody [1H9L17] (ab203570) at 0.1 µg/ml
Lane 1 : Mouse Esophagus
Lane 2 : Mouse skin
Lane 3 : Mouse Skeletal muscle
Lane 4 : Jurkat
Lane 5 : Hep G2
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat anti-Rabbit IgG - HRP Secondary Antibody at 0.02 µg/ml
Predicted band size: 11 kDaWestern blot analysis of SUMO-3 expression in Mouse Esophagus, Mouse Skin, Mouse Skeletal muscle, and human cell lines Jurkat and HepG2. Used Novex® NuPAGE®4-12 % Bis-Tris gel, XCell SureLock™ Electrophoresis System, Novex® Sharp Pre-Stained Protein Standard, and iBlot® Dry Blotting System. Proteins were transferred to a nitrocellulose membrane and blocked with 5 % skim milk for 1 hour at room temperature.SUMO-3 was detected at ~ 20 kDa using ab203570 in 5 % skim milk at 4°C overnight on a rocking platform. Chemiluminescent detection was performed using Pierce™ ECL Western blotting Substrate. -
Immunofluorescence analysis of 70% confluent log phase MCF7 cell labelled for SMT3/ SUMO3 using ab207570 at 1µg/mL. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with ab203570 in 1% BSA and incubated for 3 hours at room temperature and then labeled with secondary antibody for 45 minutes at room temperature (Panel A: green). Nuclei (Panel B: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI. F-actin (Panel C: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin(1/300). Panel D is a merged image showing Nuclear localization. Panel E is a no primary antibody control. The images were captured at 60X magnification.
-
Immunohistochemical analysis of formalin fixed, paraffin embedded Human colon carcinoma tissue labeling Sumo 3 using ab203570 at 5 μg/mL, followed by DAB detection.
-
Immunofluorescent analysis of U2OS cells labeling Sumo 3 using ab203570 at 5 μg/mL (left image). Right image: sample with immunogenic phosphopeptide. Alexa Fluor® 488 Goat anti-Rabbit at 1/1000 dilution was used as secondary antibody.
-
Flow cytometric analysis of fixed and permealized Jurkat cells labeling Sumo 3 using ab203570 at 0.5 μg/test (Black) followed by secondary detection with Alexa Fluor® 488 Goat anti-Rabbit. Cells incubated without primary antibody (grey) for control. Preincubation with immunizing peptide decreased the staining (red).
Protocols
Datasheets and documents
-
Datasheet download
References (3)
ab203570 has been referenced in 3 publications.
- Tong Y et al. Hypoxia-induced NFATc3 deSUMOylation enhances pancreatic carcinoma progression. Cell Death Dis 13:413 (2022). PubMed: 35484132
- Lin Y et al. An immunohistochemical panel of three small ubiquitin-like modifier genes predicts outcomes of patients with triple-negative breast cancer. Gland Surg 10:1067-1084 (2021). PubMed: 33842251
- Chen C et al. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer. J Clin Invest 131:N/A (2021). PubMed: 33661764